The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AGN-PC-00FPU4     N,N'-bis(1,3-dihydroxypropan- 2-yl)-5-(2...

Synonyms: Bracco 15000, KST-1A7044, AC1L1GLB, AC1Q4PBS, AR-1A7896, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of iopamidol


Psychiatry related information on iopamidol


High impact information on iopamidol


Chemical compound and disease context of iopamidol


Biological context of iopamidol

  • Iopamidol (1.5 ml kg-1) caused a moderate decrease in pulmonary and systemic vascular resistance, slight increases in right ventricular end-diastolic pressure and a marked rise in right ventricular contractility (dP/dtmax) [16].
  • Heart rate, cardiac output and right atrial pressure rose significantly more after amidotrizoate and this contrast medium caused more extensive systemic vasodilation and a larger decrease in aortic pressure as compared to iopamidol [16].
  • RESULTS: Ioxaglate did not activate platelets, but evidence of platelet activation by iohexol and iopamidol was found in blood from two and three healthy volunteers, respectively, of the six volunteers studied [17].
  • RESULTS: The radiocontrast agents reduced cell viability to a greater extent than hyperosmolal mannitol solutions in both cell lines; diatrizoate was more toxic than iopamidol [18].
  • Analysis of continuous 48-hour ECGs showed that both ioxaglate and iopamidol induced a slight increase (by 8% and 7%, respectively; p less than 0.05) in heart rate during injection with early and complete recovery.(ABSTRACT TRUNCATED AT 250 WORDS)[19]

Anatomical context of iopamidol


Associations of iopamidol with other chemical compounds


Gene context of iopamidol

  • Decrease (20 - 40%) of platelet aggregation occurred at T1, whichever platelet aggregating agent (ADP, collagen, Ristocetin or thrombin) were used (significant after Iopamidol 300 and Na Meg Ioxaglate) [30].
  • Ioxaglate and iopamidol both increased the prothrombotic factors vWF and PAI-1 to the same degree indicating a similar risk of thrombogenicity between low-osmolal ionic and non-ionic radiocontrast agents in this in vitro model [31].
  • We have attempted to develop murine models to determine whether or not anaphylactic antibodies such as IgE and IgG1 against hapten (DNP) were enhanced with contrast medium (iopamidol) as an adjuvant or if the contrast medium itself produced antibodies of the IgE class [32].
  • The maximum increase of GGT excretion was, however, statistically significantly lower in the group treated with iopromide than in the iopamidol group [33].
  • With diabetes a more pronounced iopamidol effect on the excretion of brush border membrane proteins and a significant increase in the excretion of villin was observed [23].

Analytical, diagnostic and therapeutic context of iopamidol


  1. Aseptic meningoencephalitis after iopamidol myelography. Mallat, Z., Vassal, T., Naouri, J.F., Prier, A., Laredo, J.D., Offenstadt, G. Lancet (1991) [Pubmed]
  2. Paraplegia after iopamidol myelography. Bain, P.G., Colchester, A.C., Nadarajah, D. Lancet (1991) [Pubmed]
  3. Seizures following myelography with iopamidol. Levey, A.I., Weiss, H., Yu, R., Wang, H., Krumholz, A. Ann. Neurol. (1988) [Pubmed]
  4. Adverse reactions of low osmolality contrast media during cardiac angiography: a prospective randomized multicenter study. Gertz, E.W., Wisneski, J.A., Miller, R., Knudtson, M., Robb, J., Dragatakis, L., Browne, K.F., Vetrovec, G., Smith, S.C. J. Am. Coll. Cardiol. (1992) [Pubmed]
  5. Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus. Carraro, M., Mancini, W., Artero, M., Zennaro, C., Faccini, L., Candido, R., Armini, L., Calci, M., Carretta, R., Fabris, B. Diabetologia (2000) [Pubmed]
  6. Transient global amnesia associated with cerebral angiography performed with use of iopamidol. Giang, D.W., Kido, D.K. Radiology. (1989) [Pubmed]
  7. Evaluation of myelographic contrast-medium tolerance with psychometric testing. Hammeke, T.A., Grogan, J.P., Haughton, V.M., Pfeiffer, M.M., Harrington, G.J., Sudilovsky, A. AJNR. American journal of neuroradiology. (1985) [Pubmed]
  8. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. Schwab, S.J., Hlatky, M.A., Pieper, K.S., Davidson, C.J., Morris, K.G., Skelton, T.N., Bashore, T.M. N. Engl. J. Med. (1989) [Pubmed]
  9. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. Russo, D., Minutolo, R., Cianciaruso, B., Memoli, B., Conte, G., De Nicola, L. J. Am. Soc. Nephrol. (1995) [Pubmed]
  10. Myocardial washout of sonicated iopamidol reflects coronary blood flow in the absence of autoregulation. Rovai, D., Ghelardini, G., Lombardi, M., Trivella, M.G., Nevola, E., Taddei, L., Michelassi, C., Distante, A., DeMaria, A.N., L'Abbate, A. J. Am. Coll. Cardiol. (1992) [Pubmed]
  11. Clinical superiority of a new nonionic contrast agent (iopamidol) for cardiac angiography. Gertz, E.W., Wisneski, J.A., Chiu, D., Akin, J.R., Hu, C. J. Am. Coll. Cardiol. (1985) [Pubmed]
  12. Risk of thromboembolism during diagnostic and interventional cardiac procedures with nonionic contrast media. Hwang, M.H., Piao, Z.E., Murdock, D.K., Messmore, H.L., Giardina, J.J., Scanlon, P.J. Radiology. (1990) [Pubmed]
  13. Low-osmolality contrast media-induced ventricular fibrillation. Hayakawa, K., Yamashita, K. Investigative radiology. (1989) [Pubmed]
  14. Absence of myocardial biochemical toxicity with a nonionic contrast agent (iopamidol). Wisneski, J.A., Gertz, E.W., Neese, R.A., Morris, D.L. Am. Heart J. (1985) [Pubmed]
  15. Contrast media induced pulmonary edema. Comparison of ionic and nonionic agents in an animal model. Måre, K., Violante, M., Zack, A. Investigative radiology. (1984) [Pubmed]
  16. The haemodynamic side-effects of ionic and non-ionic contrast media in the presence of pulmonary hypertension: experimental and clinical investigation. Schräder, R., Hellige, G., Kaltenbach, M., Kober, G. Eur. Heart J. (1987) [Pubmed]
  17. Activation of platelets by low-osmolar contrast media: differential effects of ionic and nonionic agents. Hardeman, M.R., Konijnenberg, A., Sturk, A., Reekers, J.A. Radiology. (1994) [Pubmed]
  18. Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers. Haller, C., Schick, C.S., Zorn, M., Kübler, W. Cardiovasc. Res. (1997) [Pubmed]
  19. Are ioxaglate and iopamidol equally safe and well tolerated in cardiac angiography? A randomized, double-blind clinical study. Piscione, F., Focaccio, A., Santinelli, V., De Paola, M., Villari, B., Spinazzi, A., Condorelli, M., Chiariello, M. Am. Heart J. (1990) [Pubmed]
  20. Chemical ablation by subendocardial injection of ethanol via catheter--preliminary results in the pig heart. Weismüller, P., Mayer, U., Richter, P., Heieck, F., Kochs, M., Hombach, V. Eur. Heart J. (1991) [Pubmed]
  21. Iopamidol: a new contrast medium in coronary angiography. Comparison, on electrophysiological changes in man, with a commonly used contrast medium. Niccoli, L., Bellandi, M., Benedini, G., Cuccia, C., Petroboni, V., Visioli, O. Eur. Heart J. (1983) [Pubmed]
  22. Breast sentinel lymph node mapping at CT lymphography with iopamidol: preliminary experience. Suga, K., Yuan, Y., Okada, M., Matsunaga, N., Tangoku, A., Yamamoto, S., Oka, M. Radiology. (2004) [Pubmed]
  23. Analysis of Na+-D-glucose cotransporter and other renal brush border proteins in human urine. Birk, H.W., Piberhofer, S., Schütterle, G., Haase, W., Kötting, J., Koepsell, H. Kidney Int. (1991) [Pubmed]
  24. Proximal tubule cell response to radiographic contrast media. Hardiek, K., Katholi, R.E., Ramkumar, V., Deitrick, C. Am. J. Physiol. Renal Physiol. (2001) [Pubmed]
  25. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. Taliercio, C.P., Vlietstra, R.E., Ilstrup, D.M., Burnett, J.C., Menke, K.K., Stensrud, S.L., Holmes, D.R. J. Am. Coll. Cardiol. (1991) [Pubmed]
  26. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Solomon, R. Kidney Int. (2005) [Pubmed]
  27. Iopamidol arteriography: discomfort and pain. Dotter, C.T., Rösch, J., Erlandson, M., Buschman, R.W., Ogilvie, R. Radiology. (1985) [Pubmed]
  28. Incompatibility of Isovue 370 and papaverine in peripheral arteriography. Pallan, T.M., Wulkan, I.A., Abadir, A.R., Flores, L., Chaudhry, M.R., Gintautas, J. Radiology. (1993) [Pubmed]
  29. Effective prophylactic protocol in delayed hypersensitivity to contrast media: report of a case involving lymphocyte transformation studies with different compounds. Romano, A., Artesani, M.C., Andriolo, M., Viola, M., Pettinato, R., Vecchioli-Scaldazza, A. Radiology. (2002) [Pubmed]
  30. Contrast agents used for excretory urography impair platelet function in human patients. Belleville, J., Freyria, A.M., Pinet, A., Cornillon, B., Paul, J., Clendinnen, G., Eloy, R. Thromb. Res. (1982) [Pubmed]
  31. Differential effects of radiocontrast agents on human umbilical vein endothelial cells: cytotoxicity and modulators of thrombogenicity. Fauser, C., Ullisch, E.V., Kübler, W., Haller, C. Eur. J. Med. Res. (2001) [Pubmed]
  32. Anaphylactic IgE and IgG1 production for hapten can be enhanced by contrast media. Miyauchi, T., Hirano, T., Ushiyama, C., Ovary, Z., Okumura, K., Katayama, H. The British journal of radiology. (1996) [Pubmed]
  33. Renal and hepatic tolerance of nonionic and ionic contrast media in intravenous digital subtraction angiography. Langer, M., Junge, W., Keysser, R., Hasford, J., Jänicke, U.A. Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin. Ergänzungsband. (1989) [Pubmed]
  34. Fatal non-cardiogenic pulmonary oedema after intravenous non-ionic radiographic contrast. Paul, R.E., George, G. Lancet (2002) [Pubmed]
  35. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Davidson, C.J., Hlatky, M., Morris, K.G., Pieper, K., Skelton, T.N., Schwab, S.J., Bashore, T.M. Ann. Intern. Med. (1989) [Pubmed]
  36. Platelet activation during coronary angioplasty in humans. Gasperetti, C.M., Gonias, S.L., Gimple, L.W., Powers, E.R. Circulation (1993) [Pubmed]
  37. Platelet and fibrin modification by radiographic contrast media. Gabriel, D.A., Jones, M.R., Reece, N.S., Boothroyd, E., Bashore, T. Circ. Res. (1991) [Pubmed]
  38. Monitoring of pancreas-graft perfusion by radionuclide and digital subtraction angiography. Rasmussen, K., Burcharth, F., Thomsen, H.S., Rygaard, H. Diabetes (1989) [Pubmed]
WikiGenes - Universities